Christine Fischette, PhD

Executive Director

 

  • CEO, BioLinkUp, LLC, a corporate strategy / business development entity

  • Independent consultant for investment banks (New York), venture capitalist and Biopharma companies

  • Advisory Board member, private companies

  • Invited Faculty for Annual BIO Business Development Fundamentals Course – Negotiations module at BIO International Conference

  • Invited Reviewer for proposals from full professors at Rockefeller University, NY to assess development and commercial potential of early stage products

  • Pitch Doctor / Panel Member Annual Life Sciences Summit, NY

 

Previous Roles

 

  • Enzo Therapeutics, Inc., a division of Enzo Biochem (ENZ: NYSE), President

  • Novartis, Head, Negotiation, Global General Medicine Business Franchise Boards

  • Pfizer, Director, Global Licensing and Development; Head of US Diabetes Marketing; Medical Director; Project Manager; Liaison for international drug co-development programs;

  • Corporate Member of FDA Drug Advisory Subcommittee for Drug Abuse

  • Hoffmann-La Roche, Senior Scientist

  • Rockefeller University, Adjunct Research Faculty/Post-Doctoral Fellow with extensive publication record, including Science

  • Founding Member and Chair, M&A Committee, Licensing Executive Society (LES); and Co-Chair, NYC Chapter Board

 

 

Since 2010, Chris has been Founder & CEO, BioLinkUp, LLC, a Corporate Strategy/Business Development entity, where she specializes in advising companies on growth strategies, business development, partnering / licensing and drug development. She consults for investment banks (NY), venture capitalists and biopharma companies as an independent consultant.

 

Christine has spent 25+ years at Roche, Pfizer and Novartis, lastly as Head of Negotiation and Board Director for several therapeutic business units at Novartis. She has served as President of a small public biotech firm, and has accumulated overarching experience in strategic and operational roles in research, drug development, commercialization, business development and general management.

 

At Pfizer she orchestrated the entire drug development/marketing process of a therapeutic from formulation selection, through clinical development (IND to NDA) to successful commercialization with net sales eventually reaching @ $350m, and eventually was Head of Pfizer’s US Commercial Franchise for Diabetes.

 

She serves(d) on private company Business/Scientific Advisory Boards for therapeutics and devices, and is a faculty member of the BIO Business Development Fundamentals Course offered annually by BIO. She was the Founding member and Chair of the M&A Committee for the USA/Canada Licensing Executive Society (LES), and Co-Chair for the LES NYC Chapter.

 

Christine continues as an invited reviewer of grant proposals at Rockefeller University to assess future development/commercialization potential, and frequently organizes and speaks at BioPharma panels at local/international BioPharma meetings. She has widespread relationships with senior management within the BioPharma industry, and has authored over 50 publications in peer-reviewed publications, including Science.

Christine received her PhD in Physiology Rutgers Biomedical Health Sciences